{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"13.9","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Time from the date of first documented response (sCR/CR/VGPR or PR) to documented disease relapse, progression or death whichever occurs first. sCR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow. CR defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow. VGPR defined as serum and urine M-protein detectable or \\> 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg/24 h. PR defined as \\> 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \\>90% or to \\< 200 mg/24 h.","dispersionType":"Full Range","groups":[{"description":"Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level #2 (4mg MLN9708)"}],"paramType":"MEDIAN","populationDescription":"Patients received 4 mg MLN9708, 4mg pomalidomide, and 40 mg dexamethasone (RP2D).","reportingStatus":"POSTED","timeFrame":"Time interval from the date of first documented response (sCR/CR/VGPR or PR) to documented disease relapse, progression or death whichever occurs first, up to 24 months","title":"Duration of Response at the Recommended Phase II Dose (RP2D)","type":"SECONDARY","unitOfMeasure":"Months"}